Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Webcasts|September 25, 2019
The Evolution of Cellulose in Tableting Technology
Author(s)JRS Pharma
From functional fillers to high functionality excipients, discover the evolution of cellulose in tableting technology. Live: Wednesday, Sept. 25, 2019 at 10am EDT | 3pm BST | 4pm CEST On demand available after airing until Sept. 25, 2020 Register free
Register free:
Event Overview:
The development of co-processed, multifunctional excipients has enabled formulators to address multiple challenges with a single excipient, resulting in enhanced production and better finished product quality. In this webcast, learn about how the evolution from traditional powdered cellulose to microcrystalline cellulose to a new generation of co-processed high functionality excipients can benefit tableting processes including continuous manufacturing applications.
Key Learning Objectives:
- How the development of microcrystalline cellulose from powdered cellulose results in different grades to address a wider range of formulation challenges
- How the application of co-processing techniques combined mono-functional excipients to create high-functionality excipients with multiple benefits and added value
- How further development from binary co-processed excipients to multi-component composites provides the user with ingredients that can reduce process complexity and enhance product quality in continuous manufacturing applications
Who Should Attend:
Scientists, managers, research and development, sales, quality, and procurement professionals at pharmaceutical, nutritional, and contract development and manufacturing organizations
Speaker: Tony E. Carpanzano, BS, RPh, Director of R&D, JRS Pharma
Time and date: Wednesday, Sept. 25, 2019 at 10am EDT | 3pm BST | 4pm CEST
On demand available after airing until Sept. 25, 2020
Sponsor: JRS Pharma
Register free:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
3
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5